AU2013305580A1 - Anxiolytic composition, formulation and method of use - Google Patents

Anxiolytic composition, formulation and method of use Download PDF

Info

Publication number
AU2013305580A1
AU2013305580A1 AU2013305580A AU2013305580A AU2013305580A1 AU 2013305580 A1 AU2013305580 A1 AU 2013305580A1 AU 2013305580 A AU2013305580 A AU 2013305580A AU 2013305580 A AU2013305580 A AU 2013305580A AU 2013305580 A1 AU2013305580 A1 AU 2013305580A1
Authority
AU
Australia
Prior art keywords
nmda receptor
receptor antagonist
anxiety
administered
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2013305580A
Other languages
English (en)
Inventor
Stuart L. Weg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of AU2013305580A1 publication Critical patent/AU2013305580A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Otolaryngology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Inorganic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2013305580A 2012-08-23 2013-08-23 Anxiolytic composition, formulation and method of use Abandoned AU2013305580A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261692380P 2012-08-23 2012-08-23
US61/692,380 2012-08-23
PCT/US2013/056424 WO2014031975A1 (en) 2012-08-23 2013-08-23 Anxiolytic composition, formulation and method of use

Publications (1)

Publication Number Publication Date
AU2013305580A1 true AU2013305580A1 (en) 2015-04-09

Family

ID=50148531

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2013305580A Abandoned AU2013305580A1 (en) 2012-08-23 2013-08-23 Anxiolytic composition, formulation and method of use

Country Status (11)

Country Link
US (4) US20140057988A1 (2)
EP (2) EP3878442A1 (2)
JP (2) JP6722453B2 (2)
KR (1) KR20150096370A (2)
CN (1) CN104902883A (2)
AU (1) AU2013305580A1 (2)
BR (1) BR112015003796A2 (2)
IL (1) IL237340A0 (2)
MX (1) MX2015002378A (2)
SG (1) SG11201501292UA (2)
WO (1) WO2014031975A1 (2)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2968221T3 (da) * 2013-03-15 2019-08-05 Janssen Pharmaceutica Nv Farmaceutisk sammensætning af s-ketaminhydrochlorid
US20140274981A1 (en) 2013-03-15 2014-09-18 Janssen Pharmaceutica Nv Pharmaceutical composition of s-ketamine hydrochloride
DK2983787T3 (da) 2013-04-12 2020-01-06 Icahn School Med Mount Sinai Fremgangsmåde til behandling af posttraumatisk stresssygdom
HUE056378T2 (hu) 2013-09-13 2022-02-28 Univ Chiba Nat Univ Corp R-Ketamin és sójának alkalmazása gyógyszerekként
KR20170040800A (ko) 2014-08-13 2017-04-13 얀센 파마슈티카 엔.브이. 우울증 치료 방법
JP6757537B2 (ja) * 2014-08-29 2020-09-23 公益財団法人ヒューマンサイエンス振興財団 神経疾患モデル動物の製造方法及び神経疾患モデル動物
AU2015318123A1 (en) 2014-09-15 2017-03-30 Janssen Pharmaceutica Nv Val66Met (SNP rs6265) genotype specific dosing regimens and methods for the treatment of depression
EP3085366A1 (en) * 2015-04-22 2016-10-26 Institut du Cerveau et de la Moelle Epiniere-ICM Nmda antagonists for the treatment of mental disorders with occurrence of aggressive and/or impulsive behavior
US20160332962A1 (en) 2015-05-13 2016-11-17 Janssen Pharmaceutica Nv (s)-csa salt of s-ketamine, (r)-csa salt of s-ketamine and processes for the preparation of s-ketamine
JP2018521007A (ja) * 2015-05-22 2018-08-02 ヴィスタゲン セラピューティクス、インコーポレイテッド Ｌ−４−クロロキヌレニンの治療的使用
CN107847469A (zh) 2015-06-27 2018-03-27 美国神农制药责任有限公司 氯胺酮透皮递送系统
CN105249531A (zh) * 2015-08-06 2016-01-20 云南中烟工业有限责任公司 一种金丝楠木提取物的制备方法及其应用
PL4023222T3 (pl) * 2015-09-08 2025-03-24 The Children's Hospital Of Philadelphia Nieselektywny aktywator metabotropowych receptorów glutaminianu do leczenia zespołu 22q
US11110070B2 (en) * 2015-11-17 2021-09-07 The Trustees Of Columbia University In The City Of New York Pharmacological prophylactics against stress-induced affective disorders and their associated symptoms
US20200009081A1 (en) 2017-09-13 2020-01-09 Janssen Pharmaceutica N.V. Delivery Of Esketamine For The Treatment Of Depression
WO2019094757A1 (en) 2017-11-09 2019-05-16 The Trustees Of Columbia University In The City Of New York Pharmacological prophylactics against stress-induced affective disorders in females
US11622948B2 (en) 2017-11-09 2023-04-11 The Trustees Of Columbia University In The City Of New York Biomarkers for efficacy of prophylactic treatments against stress-induced affective disorders
FR3075038B1 (fr) 2017-12-15 2020-03-06 Melchior Material And Life Science France Utilisation de la fluoroethylnormemantine pour la prevention de l'apparition et le traitement de l'anxiete
KR20240011237A (ko) 2017-12-22 2024-01-25 얀센 파마슈티카 엔브이 우울증 치료를 위한 에스케타민
ES2907692T3 (es) 2017-12-29 2022-04-26 Celon Pharma Sa Composición de ketamina de polvo seco para su administración por vía pulmonar en la depresión resistente al tratamiento
US11980595B2 (en) 2018-02-15 2024-05-14 National University Corporation Chiba University Preventive or therapeutic agent and pharmaceutical composition for inflammatory diseases or bone diseases
WO2019213551A1 (en) 2018-05-04 2019-11-07 Perception Neuroscience, Inc. Methods of treating substance abuse
US12090145B2 (en) * 2018-08-20 2024-09-17 Yale University Combination therapy for treating or preventing depression or other mood diseases
EP3928906A4 (en) 2019-02-22 2022-11-23 Harima Chemicals, Incorporated Method for applying solid brazing material, method for manufacturing coated object, application device, and roll-shaped solid brazing material
JP2022524008A (ja) 2019-03-05 2022-04-27 ヤンセン ファーマシューティカルズ，インコーポレーテッド うつ病の治療のためのエスケタミン
EP3968977A4 (en) * 2019-05-15 2023-01-11 The Trustees of Columbia University in the City of New York COMPOSITIONS AND METHODS AGAINST STRESS-INDUCED MOOD DISORDERS AND THEIR ASSOCIATED SYMPTOMS
PT3976012T (pt) * 2019-05-31 2024-04-09 Afyx Therapeutics As Administração intranasal de cetamina a doentes com cefaleia em salvas
JP2023511370A (ja) 2020-01-22 2023-03-17 シーロス セラピューティクス， インコーポレイテッド Ｎｍｄａ拮抗薬の副作用の低減

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5543434A (en) * 1994-02-25 1996-08-06 Weg; Stuart L. Nasal administration of ketamine to manage pain
US5679714A (en) * 1995-06-07 1997-10-21 Weg; Stuart L. Administration of ketamine for detoxification and treatment of tobacco addiction
US6248789B1 (en) 1996-08-29 2001-06-19 Stuart L. Weg Administration of ketamine to manage pain and to reduce drug dependency
US6391922B1 (en) * 1998-01-13 2002-05-21 Synchroneuron, Llc Treatment of posttraumatic stress disorder, obsessive-compulsive disorder and related neuropsychiatric disorders
EP1103256A1 (de) * 1999-11-26 2001-05-30 Claudius Dr. med. Böck Verwendung von Ketamin zur Behandlung von neuroendokriner Immundysfunktion und algogenem Psychosyndrom
AU2007229866A1 (en) * 2006-03-22 2007-10-04 Mount Sinai School Of Medicine Intranasal administration of ketamine to treat depression
BRPI0809843A2 (pt) * 2007-04-26 2014-09-23 Auspex Pharmaceuticals Inc "composto, composição farmacêutica e uso de um composto"
US20110038807A1 (en) * 2009-08-14 2011-02-17 Demitri Papolos Compositions and methods for treating bipolar disorder

Also Published As

Publication number Publication date
US20250255834A1 (en) 2025-08-14
US20180235906A1 (en) 2018-08-23
WO2014031975A1 (en) 2014-02-27
IL237340A0 (en) 2015-04-30
EP2887930A4 (en) 2016-03-23
US20140057988A1 (en) 2014-02-27
BR112015003796A2 (pt) 2017-07-04
JP6722453B2 (ja) 2020-07-15
JP2018162302A (ja) 2018-10-18
EP3878442A1 (en) 2021-09-15
EP2887930A1 (en) 2015-07-01
CN104902883A (zh) 2015-09-09
KR20150096370A (ko) 2015-08-24
US20220160655A1 (en) 2022-05-26
MX2015002378A (es) 2015-09-25
JP2016501828A (ja) 2016-01-21
SG11201501292UA (en) 2015-05-28
JP6771512B2 (ja) 2020-10-21

Similar Documents

Publication Publication Date Title
US20250255834A1 (en) Anxiolytic composition, formulation and method of use
US5543434A (en) Nasal administration of ketamine to manage pain
Raval et al. Oral clonidine pre medication for attenuation of haemodynamic response to laryngoscopy and intubation
JP2009530385A (ja) うつ病の治療のためのケタミンの鼻内投与
MXPA96003633A (en) Use of ketamine and device for the nasal and eye administration of ketamine for the management of pain and for detoxification
JP7705348B2 (ja) 睡眠時無呼吸を治療するための方法および組成物
US20070066996A1 (en) Modafinil-based neurorehabilitation of impaired neurological function associated with brian injury
TW200918048A (en) Drug combinations for the treatment of sialorrhoea
JP2016535027A (ja) 非角化重層上皮（ＮＫＳＥ）組織の不快感の治療用局所薬としての１−ジ（ｓｅｃ−ブチル）−ホスフィノイル−ペンタン（ＤＡＰＡ−２−５）
Esmat et al. Comparative study between transdermal nicotine and melatonin patches on postoperative pain relief after laparoscopic cholecystectomy, a double-blind, placebo-controlled trial
Esmat et al. Comparative study between transdermal fentanyl and melatonin patches on postoperative pain relief after lumber laminectomy, a double-blind, placebo-controlled trial
Mogahed et al. The effect of adding two different doses of magnesium sulphate as adjuvant to ropivacaine in peribulbar block for cataract surgery
Mohamed et al. Fentanyl versus midazolam as additive to local anesthetic mixture for peribulbar block during posterior segment surgery in adult patients a prospective randomized double-blind study
Hirakawa et al. A case of facial pain in somatic symptom disorder responding to duloxetine
Shan-su et al. Effects of intravenous infusion of esketamine on analgesia and postpartum antidepressant after cesarean section.
Busara Sirivanasandha et al. Recovery profiles after general anesthesia in patients undergoing anterior cervical discectomy and fusion (ACDF) surgery with or without dexmedetomidine as an anesthetic adjuvant: a double blinded randomized study
Hosni et al. Efficacy of a premedication with melatonin during cataract surgery under peribulbar block: Study protocol for a prospective randomized double-blinded study
Hafiani et al. Administration of nebulised ketamine for managing pain in the intensiv e care unit of obstetrics and gynaecology
Zanza et al. Effectiveness of Intranasal Analgesia in The Emergency
Tay et al. Knowing the Emergency Drugs in your Dental Practice
Wong et al. Sedation and Analgesia for HIFU Ablation
Ahuja A Comparitive Clinical Evaluation of Dexmedetomidine V/S Propofol in Patients Undergoing Extraction of Impacted Mandibular Third Molars
Moses Intravenous sedation with dexmedetomidine and midazolam for third molar extraction
Wutzke Intraoperative Ketamine to Reduce Postoperative Opioid Consumption in Chronic Pain Patients
Islam et al. Study on Efficacy of Nalbuphine Hydrochloride as Pre-Emptive Analgesic Comparison With Diclofenac Sodium after Open Cholecystectomy

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period